Creating a Movement in Dermatology: Clear Horizons UK
Summary of work
In moderate-to-severe psoriasis, IL-23 inhibitors are ground breaking in terms of durable efficacy and favourable safety. However, IL-23 inhibitor-uptake in the UK has faced unique challenges, including risk aversion to biologic use, lack of experience with the new IL-23 inhibitor, SKYRIZI, and the COVID-19 pandemic. CLEAR HORIZONS was designed to establish an IL-23/SKYRIZI expert community to connect and share expertise and drive change to clinical practice at a local level.
In the UK, a committed and influential group of 31 change leaders informed the comprehensive CLEAR HORIZONS programme, delivering 46 meetings to over 1400 healthcare professionals. By providing experiential education, the CLEAR HORIZONS programme is unique in enabling UK healthcare professionals to share knowledge and enthusiasm for improving patient outcomes with biologics, including SKYRIZI. Early findings suggest that, despite COVID-19 reducing clinic attendance, IL-23-inhibitors show significant growth, representing nearly 50% of the UK market. Indeed, SKYRIZI is on track to be the fastest biologic in terms of launch uptake – and one of only a few to grow over the last year. By establishing a bigger, more united and inspired community than ever before, the CLEAR HORIZONS programme has encouraged the majority of partaking nurses and dermatologists to change clinical practice.
This entry from Lucid and AbbVie provided a very clear outline of the landscape and the challenge, with well-defined objectives, a purposeful strategy and well-rounded implementation. The engagement numbers were strong and there was a good intent to change behaviour. A solid and effective initiative